Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 HKEX Manufacturing
Open in API
Filings indexed 236 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER
Regulatory Filings
2026-05-06 English
(1) PROPOSED APPOINTMENT OF SUPERVISOR; (2) PROPOSED CHANGE OF REGISTERED ADDRESS; AND (3) PROPOSED AMENDMENTS OF THE ARTICLES OF ASSOCIATION
Board/Management Information Classification · 1% confidence The document is an official announcement on the Hong Kong Stock Exchange concerning the proposed appointment of a supervisor (a board-level position), a change of registered address, and amendments to the Articles of Association. It details the biography of the proposed supervisor, terms of office, and governance changes. This fits Squarely under “Board/Management Information” (Code: MANG), as it announces changes in the company’s supervisory board and governance structure rather than presenting full financial results or requesting shareholder votes via proxy materials.
2026-04-27 English
Proxy Form for the Annual General Meeting to be held on May 19, 2026
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a proxy form for the Annual General Meeting, providing shareholders instructions on appointing proxies and voting on resolutions. It is part of the solicitation materials sent to shareholders to request their votes at the AGM. This matches the definition of a Proxy Solicitation & Information Statement.
2026-04-27 English
(1) 2025 REPORT OF THE BOARD OF DIRECTORS (2) 2025 REPORT OF THE BOARD OF SUPERVISORS (3) 2025 ANNUAL REPORT (4) 2025 FINANCIAL ACCOUNTS REPORT (5) 2026 FINANCIAL BUDGET (6) 2025 ANNUAL PROFIT DISTRIB
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a shareholder circular containing the notice of the 2025 Annual General Meeting, detailed resolutions to be voted on, the form of proxy, and background information (reports of the board, proposed amendments, etc.). It is clearly a proxy solicitation/information statement sent to shareholders to request votes at the AGM. This matches the definition for Proxy Solicitation & Information Statement (PSI).
2026-04-27 English
NOTICE OF THE 2025 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice convening the 2025 Annual General Meeting, setting out the date, venue, agenda items, resolutions to be voted on, proxy appointment procedures, and share registration details—all hallmarks of materials sent to shareholders to provide information and solicit votes ahead of a general meeting. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-27 English
2025 Annual Report
Annual Report Classification · 1% confidence The document is explicitly titled '2025 Annual Report' and contains comprehensive sections including 'Chairman's Statement', 'Management Discussion and Analysis', 'Independent Auditor's Report', and 'Consolidated Financial Statements'. It covers the company's full-year performance, financial results, and operational highlights for the fiscal year 2025. It is clearly the primary annual financial reporting document for Lepu Biopharma Co., Ltd. FY 2025
2026-04-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.